ADCT-301

ADCT-301

About ADCT-301 (camidanlumab tesirine)

ADCT-301 (camidanlumab tesirine) is an antibody drug conjugate (ADC) composed of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to a pyrrolobenzodiazepine (PBD) dimer toxin. Once bound to a CD25-expresing cell, ADCT-301 is internalized into the cell where enzymes release the PBD-based warhead. In addition to CD25-expressing tumor cells, ADCT-301 depletes CD25-positive Tregs in the local tumor environment, which enhances immune- mediated anti-tumor activity.

ADCT-301 is being evaluated in Phase I clinical trials in patients with relapsed and refractory Hodgkin lymphoma and non-Hodgkin lymphoma (ClinicalTrials.gov Identifier NCT02432235), as well as a Phase Ib trial in various advanced solid tumors (NCT03621982).

Interim First-in-Human Data

ADCT-301 continues to demonstrate manageable toxicity and strong single-agent anti-tumor activity in heavily pretreated patients with relapsed or refractory Hodgkin lymphoma. Updated data from the ongoing 113-patient Phase I clinical trial of ADCT-301 were presented at the 60th American Society of Hematology (ASH) Annual Meeting.

ADCT-301 / ASH 2018